Santarus (NASDAQ:SNTS): Closing price $12.52
The firm has received FDA approval of Uceris extended release tablets for the induction of remission in patients suffering from active, mild to moderate ulcerative colitis. It is anticipated that the commercial launch of Uceris can be started in March. At the same time, management guided its fiscal year 2013 revenue above expectations, currently expecting that revenue at between $320 million and 325 million, against consensus of $301.25 million. Santarus also expects to meet or exceed its fiscal year 2012 revenue estimate of around $210 million, versus consensus of $209.33 million. Shares closed up 10.99 percent on the day at $12.52, having been traded in a 52-week range of $4.17 to $11.99.